A DOUBLE BLIND TRIAL TO COMPARE THE EFFICACY OF VITAMIN E TO A PLACEBO IN THE TREATMENT OF FIBROADENOSIS OF BREAST.

Main Article Content

Dr Kiran Prabhakar Rebello
Dr Amol Rebello
Dr. A. K. Singh
Dr Anjali Chitale

Keywords

Fibroadenosis, Vitamin E

Abstract

One woman in four is referred to a breast clinic at some time in her life. A breast lump, which may be painful, and breast pain constitute over 80% of the breast problems that require hospital referral, and breast problems constitute up to a quarter of all women in the general surgical workload1.


Fibroadenosis or FBD affects a large number of women during their Reproductive years2. It has been reported to occur in 25% to 50% of women during reproductive life.


Mastalgia the main symptom of Fibroadenosis is a common breast symptom that may affect up to 70% of women in their lifetime3.And is the reason for 50% of all referrals to breast clinics.4


After a thorough history, examination and imaging, reassurance has been reported to have an 85% success rate as a first line treatment in mastalgia5


Many different drugs like Danazol, Tamoxifen, Bromocriptine, have been tried but have been abandoned due to their side effects.


All the clinical trials investigating the possible use of Vitamin E in the treatment of Fibroadenosis of Breast have shown conflicting results.


Thus use of Vitamin E in Fibrocystic Breast Disease is still a debated topic & needs further research to determine its effectiveness.


Therefore this study was undertaken to study the role of Vitamin E in the treatment of Fibroadenosis of Breast. The primary objective of this study was to compare the efficacy of Vitamin E to a placebo in the treatment of Fibroadenosis Breast. The safety and tolerability of Vitamin E are the secondary objectives.

Abstract 63 | pdf Downloads 7

References

1. J Michael Dixon, and Jeremy Thomas, ABC of Breast Diseases, Fourth edition. 2012, Ch1, page 1
2. Pamela Chart & Brad Petrisor, G. Taylor, M.D. Benign Breast Disease by 1996 page 2, 4.
3. Roberts MM, Elton RA, Robinson SE, French K. Consultations for breast disease in general practice and hospital referral patterns. Br J Surg 1987;74:1020-2.
4. LYDIA CAI RNCROSS, MASTALGIA CMEJ, NOV/DEC 2010 Vol.28 No.11
5. Hughes LE, Mansel RE, Webster DJT. Benign disorders and diseases of the breast. Concepts and clinical management. London: Balliere-Tindall; 1989. p. 75-92
6. London RS, Sundaram GS, Murphy L, Manimekalai S, Reynolds M, Goldstein PJ. The effect of vitamin E on mammary dysplasia: a double-blind study. Obstet Gynecol 1985;65:104–6.
7. Meyer EC, Sommers DK, Reitz CJ, Mentis H.Surgery. 1990 May;107(5):549-51. Vitamin E and benign breast disease.
8. Ernster VL, Goodson WH, Hunt TK, Petrakis NL, Sickles EA, Miike R. Vitamin E and benign breast “disease”: a double-blind, randomized clinical trial. Surgery 1985;97(4):490–4.
9. Vera Rosolowich, Elizabeth Saettler, MD, FRCSC, Winnipeg MBBeth Szuck, BA, HEc, CACE, RD, Winnipeg MB Mastalgia, J Obstet Gynaecol Can 2006;28(1):49-60
10. Pruthi S, Wahner-Roedler DL, Torkelson CJ, Cha SS, Thicke LS, Hazelton JH,
11. Bauer BA. Vitamin E and evening primrose oil for management of cyclical mastalgia: a randomized pilot study. Altern Med Rev. 2010 Apr;15(1):59-67.
12. Chapman R.C, Syrjala .LK, Measurement of pain. In Loeser J.D, Butler SH, Chapman RC, Turk DC, editors. Bonica’s Management of pain. 3rd edition part 2. Philadelphia: Lippincott Williams & wilkins; 2001.p.40.
13. Mansel RE, Fenn NJ , Davies EL.Benign Breast diseases and its management.Recent Advances in surgery 21.1998:71-83.
14. Vera Rosolowich, Elizabeth Saettler, MD, FRCSC, Winnipeg MBBeth Szuck, BA, HEc, CACE, RD, Winnipeg MB Mastalgia, J Obstet Gynaecol Can 2006;28(1):49-60
15. Parsay, S., Olfati, F. and Nahidi, S. (2009), Therapeutic Effects of Vitamin E on Cyclic Mastalgia. The Breast Journal, 15: 510–514. doi: 10.1111/j.1524-4741.2009.00768.